Compile Data Set for Download or QSAR
maximum 50k data
Found 328 with Last Name = 'zawadzka' and Initial = 'a'
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105212(2-(4-Nonyl-piperazin-1-yl)-6-nitroquinoline (9))
Affinity DataKi:  1.80nM ΔG°:  -49.9kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105213(2-(4-Decyl-piperazin-1-yl)-6-nitroquinoline (10))
Affinity DataKi:  4.5nM ΔG°:  -47.6kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105214(2-(4-Undecyl-piperazin-1-yl)-6-nitroquinoline (11))
Affinity DataKi:  12.6nM ΔG°:  -45.1kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105215(2-(4-Dodecyl-piperazin-1-yl)-6-nitroquinoline (12))
Affinity DataKi:  16.1nM ΔG°:  -44.5kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105211(2-(4-Octyl-piperazin-1-yl)-6-nitroquinoline (8))
Affinity DataKi:  20.8nM ΔG°:  -43.8kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105207(2-(4-Butyl-piperazin-1-yl)-6-nitroquinoline (4))
Affinity DataKi:  24nM ΔG°:  -43.5kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105210(2-(4-Heptyl-piperazin-1-yl)-6-nitroquinoline (7))
Affinity DataKi:  54.1nM ΔG°:  -41.5kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105209(2-(4-Hexyl-piperazin-1-yl)-6-nitroquinoline (6))
Affinity DataKi:  72.9nM ΔG°:  -40.7kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105208(2-(4-Pentyl-piperazin-1-yl)-6-nitroquinoline (5))
Affinity DataKi:  80.5nM ΔG°:  -40.5kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105205(2-(4-Ethyl-piperazin-1-yl)-6-nitroquinoline (2))
Affinity DataKi:  86.1nM ΔG°:  -40.3kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105206(2-(4-Propyl-piperazin-1-yl)-6-nitroquinoline (3))
Affinity DataKi:  496nM ΔG°:  -36.0kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSodium-dependent serotonin transporter(Rattus norvegicus (rat))
University of Troms£

LigandPNGBDBM105204(2-(4-Methyl-piperazin-1-yl)-6-nitroquinoline (1))
Affinity DataKi:  1.30E+3nM ΔG°:  -33.6kJ/molepH: 7.7 T: 2°CAssay Description:The assay was performed in accordance with the method described by Owens et al. with slight modifications. Rat cerebral cortex was homogenized in 30...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575601(CHEMBL4858933)
Affinity DataIC50:  0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575593(CHEMBL4878832)
Affinity DataIC50:  0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575591(CHEMBL4850183)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575588(CHEMBL4854038)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575590(CHEMBL4864361)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575600(CHEMBL4873487)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCholinesterase(Homo sapiens (Human))
Uniwersytet Warszawski

US Patent
LigandPNGBDBM132084(US8841453, 15)
Affinity DataIC50:  0.240nMAssay Description:The biological activity of the compounds of general formula (I) towards the cholinesterase inhibition was evaluated using Ellman's method (Ellman, G....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCholinesterase(Homo sapiens (Human))
Uniwersytet Warszawski

US Patent
LigandPNGBDBM132080(US8841453, 11)
Affinity DataIC50:  0.25nMAssay Description:The biological activity of the compounds of general formula (I) towards the cholinesterase inhibition was evaluated using Ellman's method (Ellman, G....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCholinesterase(Homo sapiens (Human))
Uniwersytet Warszawski

US Patent
LigandPNGBDBM132071(US8841453, 1)
Affinity DataIC50:  0.25nMAssay Description:The biological activity of the compounds of general formula (I) towards the cholinesterase inhibition was evaluated using Ellman's method (Ellman, G....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCholinesterase(Homo sapiens (Human))
Uniwersytet Warszawski

US Patent
LigandPNGBDBM132083(US8841453, 14)
Affinity DataIC50:  0.280nMAssay Description:The biological activity of the compounds of general formula (I) towards the cholinesterase inhibition was evaluated using Ellman's method (Ellman, G....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575599(CHEMBL4848140)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575592(CHEMBL4860917)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575587(CHEMBL4852516)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575586(CHEMBL4848442)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCholinesterase(Homo sapiens (Human))
Uniwersytet Warszawski

US Patent
LigandPNGBDBM132074(US8841453, 4)
Affinity DataIC50:  0.380nMAssay Description:The biological activity of the compounds of general formula (I) towards the cholinesterase inhibition was evaluated using Ellman's method (Ellman, G....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575594(CHEMBL4856793)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575568(CHEMBL4870385)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575604(CHEMBL4873956)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575594(CHEMBL4856793)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575596(CHEMBL4848114)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575589(CHEMBL4877684)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575597(CHEMBL4861509)
Affinity DataIC50:  0.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575579(CHEMBL4847817)
Affinity DataIC50:  0.600nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575565(CHEMBL4864280)
Affinity DataIC50:  0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575576(CHEMBL4874906)
Affinity DataIC50:  0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCholinesterase(Homo sapiens (Human))
Uniwersytet Warszawski

US Patent
LigandPNGBDBM132088(US8841453, 17)
Affinity DataIC50:  0.780nMAssay Description:The biological activity of the compounds of general formula (I) towards the cholinesterase inhibition was evaluated using Ellman's method (Ellman, G....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575606(CHEMBL4856040)
Affinity DataIC50:  0.800nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCholinesterase(Homo sapiens (Human))
Uniwersytet Warszawski

US Patent
LigandPNGBDBM132081(US8841453, 12)
Affinity DataIC50:  0.880nMAssay Description:The biological activity of the compounds of general formula (I) towards the cholinesterase inhibition was evaluated using Ellman's method (Ellman, G....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575595(CHEMBL4849766)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575575(CHEMBL4870143)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575555(CHEMBL4878088)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM462705(US10780090, Compound I-43 | {(1R,2S,4R)-4-[(5-{[4-...)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575581(CHEMBL4860263)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575605(CHEMBL4865157)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM462958(US10780090, Compound I-263a | US10780090, Compound...)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575581(CHEMBL4860263)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575571(CHEMBL4861240)
Affinity DataIC50:  1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50575570(CHEMBL4865787)
Affinity DataIC50:  1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 328 total ) | Next | Last >>
Jump to: